Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

Revenues (based on the geographic location from which the sale originated):

	Years ended December 31,
(In millions)	2016		2015		2014
Ireland	$	41.6	$	14.1	$	18.5
United States	7,666.9		4,659.2		4,174.1
Rest of the world	3,688.1		1,743.4		1,829.5
Total revenues	$	11,396.6	$	6,416.7	$	6,022.1

Long-lived assets comprise all non-current assets, (excluding goodwill and intangible assets, deferred contingent consideration assets, deferred tax assets, investments and financial instruments) based on their relevant geographic location:

	Years ended December 31,
(In millions)	2016		2015
Ireland	$	41.2	$	1.7
United States	6,449.4		751.3
Rest of the world	84.0		82.2
Total	$	6,574.6	$	835.2

Schedule of Revenue by Major Customers by Reporting Segments

In the periods set out below, certain customers accounted for greater than 10% of the Company’s Product sales:

	Years ended December 31,
	2016		2016	2015		2015	2014		2014
(in millions, except %)			% Product sales			% Product sales			% Product sales
AmerisourceBergen Corp	$	1,695.3	16	$	1,048.3	17	$	759.2	13
McKesson Corp.	1,336.7		12	1,044.1		17	1,021.0		18
Cardinal Health Inc.	1,052.2		10	796.9		13	979.9		17

Schedule of Trade Receivables by Major Customers by Reporting Segments

Amounts outstanding in respect of these material customers were as follows:

	December 31,
(In millions)	2016		2015
AmerisourceBergen Corp	$	427.2	$	171.5
McKesson Corp.	312.9		193.1
Cardinal Health Inc.	278.4		181.7

Schedule of Segment Revenue from Major Products

In the periods set out below, revenues by major product were as follows:

	December 31,		December 31,		December 31,
(In millions)	2016		2015		2014
Product sales:
HEMOPHILIA	$	1,789.0	$	—	$	—
INHIBITOR THERAPIES	451.8		—		—
Hematology total	2,240.8		—		—
CINRYZE	680.2		617.7		503.0
ELAPRASE	589.0		552.6		592.8
FIRAZYR	578.5		445.0		364.2
REPLAGAL	452.4		441.2		500.4
VPRIV	345.7		342.4		366.7
KALBITOR	52.2		—		—
Genetic Diseases total	2,698.0		2,398.9		2,327.1
VYVANSE	2,013.9		1,722.2		1,449.0
ADDERALL XR	363.8		362.8		383.2
Other Neuroscience	112.8		115.4		372.3
Neuroscience total	2,490.5		2,200.4		2,204.5
IMMUNOGLOBULIN THERAPIES	1,143.9		—		—
BIO THERAPEUTICS	372.2		—		—
Immunology total	1,516.1		—		—
LIALDA/MEZAVANT	792.1		684.4		633.8
PENTASA	309.4		305.8		289.7
GATTEX/REVESTIVE	219.4		141.7		—
NATPARA	85.3		24.4		—
Other Internal Medicine	349.3		344.3		375.3
Internal Medicine total	1,755.5		1,500.6		1,298.8
Oncology total	130.5		—		—
Ophthalmology Total	54.4		—		—
Total Product sales	$	10,885.8	$	6,099.9	$	5,830.4